Defendant Name:
Allarity Therapeutics, Inc.
Defendant Type:
Public Company
Document Reference:
33-11367-s
Document Details
Legal Case Name
In the Matter of Allarity Therapeutics, Inc.
Document Name
Biopharmaceutical Company Settles Charges for Disclosure Failures
Document Date
12-Mar-2025
Document Format
Administrative Proceeding
Allegation Type
Issuer Reporting and Disclosure
Document Summary
On March 12, 2025, the SEC "today announced settled charges against Massachusetts-based biopharmaceutical company Allarity Therapeutics, Inc. for disclosure failures through the conduct of certain former officers that concealed from the public a harsh critique levied by the Food and Drug Administration(FDA) in February 2020 about the likelihood that dovitinib, Allarity's flagship cancer drug candidate, would be approved by the FDA. Allarity has agreed to pay $2.5 million to settle the charges."
Disgorgement & Penalty Information
Resolutions
Cease and Desist Order
Monetary Penalties:
Civil Penalty
Individual:
$2,500,000.00
Shared:
